环氧化酶2和E钙黏素与胰腺癌的关系(2)-找论文网

　　3 COX2和Ecad与胰腺癌预后

　　近年来的研究表明，肿瘤组织中COX2的表达和Ecad基因异常表达多与患者的不良预后相关。在胰腺癌中，单独粘附异常和合并Ecad的下调似乎反映了肿瘤侵袭性和预后差的阳性标志物，Ecad基因异常表达与胰腺癌细胞分化、增殖和淋巴结转移及肝转移密切相关[21]，在胰腺癌的发生、发展、肿瘤的浸润和转移中起重要作用。Oshima[22]等发现，剔除了APC△716基因的小鼠在肠息肉发生的早期，即有COX2表达的增多，如去除此小鼠的COX2基因，则肠息肉形成受阻。由此认为COX2基因可能与APC基因相关联，并相互调控。而APC基因产物又与E钙黏素的配体β连环素相关联。胰腺癌的发生、发展是个多步骤、多因素综合作用的结果， COX2与E钙黏素的表达呈负相关，提示可能是通过APC为中介，影响着两者之间的表达。COX2基因异常表达和Ecad的过表达是反映胰腺癌预后的有用指标。

　　4 结语与展望

　　综上所述，诸多研究结果都为COX2和Ecad在肿瘤的发生、发展中的重要作用提供了有力的证据，COX2和Ecad异常表达在肿瘤浸润和转移中起关键作用。选择性COX2抑制剂的深入研究及临床应用有望在肿瘤的早期预防及复发转移的防治中取得突破性进展[23]。COX2异常表达和Ecad在胰腺癌组织中低表达，可能成为胰腺癌治疗的新靶点。

　　Ecad和COX2的异常表达，可能是胰腺癌发生、发展众多步骤中较为关键的环节，而且，这两者之间有很好的依从性，是一种较好反映胰腺癌恶性程度和转移性的肿瘤生物学标志物。术后对胰腺癌标本进行联合检测,两者可作为胰腺癌预后的判断指标，有助于临床医生对肿瘤的生物学特征作出正确的判断，为胰腺癌术后是否服用环氧化酶2抑制剂及采取其他综合治疗作出合理选择提供理论依据。

【参考文献】
　　［1］ Costa C, Soares R, Reisfilho JS, et al. Cyclooxygenase 2 expression in associated with angiogenesis and lymph node meta in human breast cancer [J].J Clin Pathol, 2002,55(6):429434.

　　［2］ Shin SJ, Kim KO, Kim MK, et al. Expression of Ecadherin and uPA and their association with the prognosis of pancreatic cancer [J]. Jpn J Clin Oncol, 2005, 35(6):342348.

　　［3］ Sugiyama T, Yoshimoto T, Sato R, et al. Endothelin1 induces cyclooxygenase2 expression and generation of reactive oxygen species in endothelial cells[J].J Cadiovasc Pharmacol, 2004, 44(1) ：53325335.

　　［4］ Soslow RA, Dannenberg AJ ,Rush D, et al.COX2 is expressed in human pulmonary, colonic and mammary tumors [J],Cancer,2000,89(12): 26372645.

　　［5］ Ohno R, Yoshinaga K, Magno RM, et al, Depth of invasion parallels increased cyclooxygenase2 levels in patients with gastric carcinoma [J]. Cancer, 2001,91(10):18761881.

　　［6］ Feffandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients[J].J Clin Onclo, 2002,20(4):987990.

　　［7］ Shiranhama T, Arima J, Akiba S, et al. Relation between cyclooxygenase2 expression and tumor invasiveness and patients’ survival in transitional cell carcinoma of the urinary bladder [J]. Cancer, 2001,92(1):188193．

　　[8] Masferrer JL, Leahy KM, Koki AT, et al. Anti ontogenetic and antitumor activities of cyclooxygenase2 inhibitors [J]. Can RES, 2000,60(5): 13061311.

　　[9] Xu XC. COX2 inhibitors in cancer treatment and prevention, a recent development [J]. Drugs, 2002, 13(2):127137.

　　[10]Shamma A, Yamamoto H, Doki Y, et al. Upregulation of cyclooxygenase2 in squamous carcinogens is of the esophagus [J]. Clin Cancer Res ,2000,6(3):12291238．

　　[11]Koshiba T, Hostani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase2 expression in pancreatic tumors[J]. Int J pancreastol, 1999,26(3):6976.

　　[12]Kasper HU, Wolf H, Drebber U, et al. Expression of inducible nitric oxide synthase and cyclooxygenase2 in pancreatic adenocarcinoma: correlation with microvessel density [J].World J Gastroenterol,2004, 10(9): 19181922.

　　[13]Hans U Kasper, Hella Wolf, Uta Drebber, et al. Expression of inducible nitric oxide synthase and cyclooxygenase2 in pancreatic enocarcinoma: Correlation with microvessel density [J]. World J Gastroenterol, 2004, 10(13):19181922.

　　[14]Hirohashi S. Inactivation of the Ecadherin mediated cell adhesion system in human cancers [J]. Am J Pathol, 1998, 15（3):333335.

　　[15]Hayashida Y, Honda K, Idogawa M, et al.Ecadherin regulates the association between betacatenin and actinin4[J].Cancer Res, 2005,65(19):88368845.

　　[16]Behrens J. Cadherins and catenins: Role in signal transduction and tumor progression [J]. Cancer and Metastasis Reviews, 1999,18(1):1530.

　　[17]AlAynati MM, Radulovich N, Riddell RH, et al. Epithelialcadherin and betacatenin expression changes in pancreatic intraepithelial neoplasia[J]. Clin Cancer Res, 2004, 10(4):12351240.

　　[18]Pignatelli M. Ansari TW, Gunter P, et al. Loss of membranous Ecadherin expression in pancreatic cancer: correlation with lymph node metastasis [J]. J Pathol, 1994,174（4）:243248.

　　[19]Shimamura T, Sakamoto M, Ino Y,et al. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to ecadherin expression[J]. J Clin Oncol, 2003, 21(4):659667.

　　[20]Shin SJ, Kim KO, Kim MK,et al. Expression of Ecadherin and uPA and their association with the prognosis of pancreatic cancer[J]. Jpn J Clin Oncol, 2005, 35(8):487.

　　[21]Shimamura T, Sakamoto M, Ino Y, et al. Dysadherin over expression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to ecadherin expression [J]. Clin Oncol, 2003, 21(4):659667.

　　[22]Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in APC delta 716 knockout mice by inhibition of cyclooxygenase 2(COX2)[J].Cell, 1996, 87(5):803809.

　　[23]Ali S, ElRayes BF, Sarkar FH, et al. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase2 pathways for pancreatic cancer therapy [J] .Mol Cancer Ther, 2005, 4(12):1943  1951.

共2页: 上一页 [1] 2

莫西沙星壳聚糖滴眼液的研制

蛋白质芯片与ELISA法对肿瘤标志物检测结果的对照研究